Valentina Bartolomeo

Dr. Valentina Bartolomeo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
DRDirk De Ruysscher
Dirk De Ruysscher
EWEls Wauters
Els Wauters
VJVerena Jendrossek
Verena Jendrossek
AFAndrea Riccardo Filippi
Andrea Riccardo Filippi
MRMarie-Pierre Revel
Marie-Pierre Revel
PPPaul Martin Putora
Paul Martin Putora
The incidence of radiation pneumonitis (RP) has decreased significantly compared to historical series, mainly due to improved radiotherapy techniques and patient selection. Nevertheless, some patients still develop RP. This guideline provides user-friendly flowcharts to address common clinical practice questions regarding RP. We summarize the current state of the art regarding the mechanisms, risk factors, diagnosis and treatment of RP. Dosimetric constraints to minimize the incidence of RP, as well as risk factors for developing RP, such as idiopathic pulmonary fibrosis (IPF) were identified. The combination of radiotherapy and medication as a risk factor for the development of RP was reviewed. RP remains a diagnosis of exclusion, but an algorithm for reaching the diagnosis has been proposed. Finally, practical approaches to the treatment of RP are outlined.


23 September 2025 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
LPL. Provenzano
L. Provenzano
MFM. Favali
M. Favali
LML. Mazzeo
L. Mazzeo
ASAndrea Spagnoletti
Andrea Spagnoletti
MRM. Ruggirello
M. Ruggirello
APA. Prelaj
A. Prelaj

13 September 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
APARSELA PRELAJ
ARSELA PRELAJ
VMVanja Miskovic
Vanja Miskovic
MSMatteo Sacco
Matteo Sacco
AFAlberto Ferrarin
Alberto Ferrarin
CLCristina Maria Licciardello
Cristina Maria Licciardello
GSGiovanni Scoazec
Giovanni Scoazec
Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I 3 LUNG ( NCT05537922 ) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based study, enrolling 2,396 patients. We integrated real-world clinical and blood (CB) data, computed tomography (CT) images, digital pathology (DP), and genomics into machine learning early fusion (MLEF) and deep learning intermediate fusion (DLIF) models. Machine learning (ML) and deep learning (DL) CB-only models achieved consistent performance across outcomes with area under the curve (AUC) up to 0.77 in the test (TEST) set. Performance drop in external validation (EXVAL) likely reflects population differences (AUC range: 0.55–0.72). AI models significantly surpassed PD-L1, Eastern Cooperative Oncology Group performance status (ECOG PS), neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and Lung Immune Prognostic Index (LIPI) score in the independent TEST set. The clinical usability study showed that lung expert and nonexpert physicians improved their prediction with the explainable AI (XAI) ML CB-only based tool. Although multimodal integration with MLEF (CB+CT+DP) was associated with higher performance, its incremental benefit remains uncertain, not translated in TEST and EXVAL. The I 3 LUNG project is a pioneering framework showing the clinical usefulness of AI tools. A prospective validation of the decision support system (both CB and multimodal) is currently undergoing in more than 2,000 patients.

4 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
VBValentina Bartolomeo
Valentina Bartolomeo
MJMandy Jongbloed
Mandy Jongbloed
WWWouter van de Worp
Wouter van de Worp
RLRamon Langen
Ramon Langen
JDJuliette Degens
Juliette Degens
Dirk De RuysscherDirk De Ruysscher
Dirk De Ruysscher
Among patients with advanced NSCLC, there is a group of patients with synchronous oligometastatic disease (sOMD), defined as a limited number of metastases detected at the time of diagnosis. As cachexia and sarcopenia are linked to poor survival, incorporating this information could assist clinicians in determining whether a radical treatment should be administered. In a retrospective multicenter study, including all patients with adequately staged (FDG-PET, brain imaging) sOMD according to the EORTC definition, we aimed to assess the relationship between cachexia and/or sarcopenia and survival. Of the 439 patients that were identified between 2015 and 2021, 234 met the criteria for inclusion and were included. The median age of the cohort was 67, 52.6% were male, and the median number of metastasis was 1. Forty-six (19.7%) patients had cachexia, thirty-four (14.5%) had sarcopenia and twenty-one (9.0%) had both. With a median follow-up of 49.7 months, median PFS and OS were 8.6 and 17.3 months, respectively. Moreover, a trend toward longer PFS was found in patients without cachexia and sarcopenia compared to those with cachexia and/or sarcopenia. In multivariate analysis, cachexia and sarcopenia were not associated with an inferior survival, irrespective of receiving radical treatment. High CRP was associated with inferior survival and could be a prognostic factor, helping the decision of clinicians in selecting patients who may benefit from the addition of LRT. However, despite the homogeneous definition of oligometastatic disease and the adequate staging, our subgroups were small. Therefore, further studies are needed to better understand our hypothesis and generating findings.

17 February 2026 in Lung Cancer
Verified
Journal Article
Open access
VBValentina Bartolomeo
Valentina Bartolomeo
MJMandy Jongbloed
Mandy Jongbloed
JHJarno W.J. Huijs
Jarno W.J. Huijs
AFAndrea Riccardo Filippi
Andrea Riccardo Filippi
BBBen E.E.M. van Den Borne
Ben E.E.M. van Den Borne
LHLizza Hendriks
Lizza Hendriks
Oligoprogressive disease (OPD) occurs when a limited number of disease sites show progression. Data on OPD incidence during systemic therapy for metastatic non-small cell lung cancer (NSCLC) are increasing, while data on progression patterns after systemic therapy with local radical treatment (LRT) in patients with synchronous oligometastatic disease (sOMD) are limited. We conducted a retrospective multicenter study to assess progression patterns, factors associated with progression and survival outcomes in sOMD NSCLC patients treated with systemic therapy and LRT. Between January 2015 and December 2022, 199 patients were included. With a median follow-up of 68.4 months, 78% experienced progression: 63% OPD and 37% widespread PD. Significant differences between OPD and widespread PD were found for performance status (62% WHO PS 0 vs 42%), tumor histology (squamous 13% vs 28%), KRAS mutation (36% vs 26%), N stage (N0-1 40% vs 21%), number (1 metastasis 72% vs 53%), and metastasis location. Patterns of PD were not associated with first-line therapy type (chemo-only vs immune checkpoint inhibitor [ICI]-based). Median PFS and OS were longer for OPD vs widespread PD: median PFS 10.5 (95% CI 8.9-12.1) vs 8.1 months (95% CI 7.7-8.6) (p < 0.001), median OS 30.9 (95% CI 23.0-38.9) vs 15.2 months (95% CI 11.4-18.9), p < 0.001. These findings suggest clinical and molecular features reflecting disease biology and may help identify patients likely to develop oligoprogression after combined therapy, a pattern associated with improved PFS and OS. Further prospective studies are needed to better predict progression and select patients benefiting from LRT.